SIMILAR PATTERN OF AMINO ACIDS MAPPED TO 'MR9'

List of Similar Pattern of Amino Acids

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click on the DrReposER ID to view details on interfaces and similar patterns of amino acids)
(Click on the view link on the last column to view superposed patterns of amino acids)

Filter list by:

	DrReposER ID / Desc.	Hit PDBID	Hit Macromolecule	Res. Matches	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1EE2_B_CHDB1250_0 (ALCOHOL DEHYDROGENASE)	2p4i	ANGIOPOIETIN-1 RECEPTOR (Homo sapiens)	3 / 3	MET A 952 LEU A 955 SER A 956	None MR9 A 301 (-4.4A) None	0.63A	1ee2A-2p4iA: undetectable	1ee2A-2p4iA: 21.73
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1IEP_A_STIA201_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL)	2p4i	ANGIOPOIETIN-1 RECEPTOR (Homo sapiens)	6 / 12	VAL A 838 ALA A 853 GLY A 908 LEU A 971 ALA A 981 ASP A 982	MR9 A 301 (-4.6A) MR9 A 301 (-3.5A) MR9 A 301 ( 3.8A) MR9 A 301 (-4.5A) MR9 A 301 (-3.2A) MR9 A 301 (-4.2A)	0.31A	1iepA-2p4iA: 10.0	1iepA-2p4iA: 37.70
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2A3A_A_TEPA1436_1 (CHITINASE)	2p4i	ANGIOPOIETIN-1 RECEPTOR (Homo sapiens)	3 / 3	ASP A 982 PHE A 960 ARG A 987	MR9 A 301 (-4.2A) MR9 A 301 ( 4.7A) None	0.83A	2a3aA-2p4iA: undetectable	2a3aA-2p4iA: 22.47
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2HYY_A_STIA600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	2p4i	ANGIOPOIETIN-1 RECEPTOR (Homo sapiens)	6 / 12	VAL A 838 ALA A 853 GLY A 908 LEU A 971 ALA A 981 ASP A 982	MR9 A 301 (-4.6A) MR9 A 301 (-3.5A) MR9 A 301 ( 3.8A) MR9 A 301 (-4.5A) MR9 A 301 (-3.2A) MR9 A 301 (-4.2A)	0.35A	2hyyA-2p4iA: 23.8	2hyyA-2p4iA: 36.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2HYY_B_STIB600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	2p4i	ANGIOPOIETIN-1 RECEPTOR (Homo sapiens)	6 / 12	VAL A 838 ALA A 853 GLY A 908 LEU A 971 ALA A 981 ASP A 982	MR9 A 301 (-4.6A) MR9 A 301 (-3.5A) MR9 A 301 ( 3.8A) MR9 A 301 (-4.5A) MR9 A 301 (-3.2A) MR9 A 301 (-4.2A)	0.39A	2hyyB-2p4iA: 23.8	2hyyB-2p4iA: 36.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2HYY_C_STIC600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	2p4i	ANGIOPOIETIN-1 RECEPTOR (Homo sapiens)	6 / 12	VAL A 838 ALA A 853 GLY A 908 LEU A 971 ALA A 981 ASP A 982	MR9 A 301 (-4.6A) MR9 A 301 (-3.5A) MR9 A 301 ( 3.8A) MR9 A 301 (-4.5A) MR9 A 301 (-3.2A) MR9 A 301 (-4.2A)	0.45A	2hyyC-2p4iA: 23.9	2hyyC-2p4iA: 36.83
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2KCE_A_D16A566_2 (THYMIDYLATE SYNTHASE)	2p4i	ANGIOPOIETIN-1 RECEPTOR (Homo sapiens)	3 / 3	HIS A 962 ILE A 885 LEU A 876	MR9 A 301 (-4.5A) MR9 A 301 ( 4.5A) MR9 A 301 ( 4.5A)	0.76A	2kceA-2p4iA: undetectable	2kceA-2p4iA: 23.49
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2OIQ_A_STIA1001_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	2p4i	ANGIOPOIETIN-1 RECEPTOR (Homo sapiens)	8 / 12	VAL A 838 ALA A 853 LYS A 855 TYR A 904 GLY A 908 LEU A 971 ALA A 981 ASP A 982	MR9 A 301 (-4.6A) MR9 A 301 (-3.5A) MR9 A 301 ( 4.6A) MR9 A 301 (-3.8A) MR9 A 301 ( 3.8A) MR9 A 301 (-4.5A) MR9 A 301 (-3.2A) MR9 A 301 (-4.2A)	0.59A	2oiqA-2p4iA: 24.0	2oiqA-2p4iA: 33.95
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2PL0_A_STIA200_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK)	2p4i	ANGIOPOIETIN-1 RECEPTOR (Homo sapiens)	7 / 12	VAL A 838 ALA A 853 LYS A 855 TYR A 904 LEU A 971 ALA A 981 ASP A 982	MR9 A 301 (-4.6A) MR9 A 301 (-3.5A) MR9 A 301 ( 4.6A) MR9 A 301 (-3.8A) MR9 A 301 (-4.5A) MR9 A 301 (-3.2A) MR9 A 301 (-4.2A)	0.54A	2pl0A-2p4iA: 22.7	2pl0A-2p4iA: 33.74
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3AQI_B_CHDB6_0 (FERROCHELATASE)	2p4i	ANGIOPOIETIN-1 RECEPTOR (Homo sapiens)	5 / 12	LEU A 910 LEU A 914 ILE A 980 SER A1033 PRO A1038	None None MR9 A 301 (-4.6A) None None	1.14A	3aqiB-2p4iA: undetectable	3aqiB-2p4iA: 21.88
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CS9_A_NILA600_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	2p4i	ANGIOPOIETIN-1 RECEPTOR (Homo sapiens)	6 / 12	ALA A 853 VAL A 875 GLY A 908 HIS A 962 LEU A 971 ALA A 981	MR9 A 301 (-3.5A) MR9 A 301 ( 4.8A) MR9 A 301 ( 3.8A) MR9 A 301 (-4.5A) MR9 A 301 (-4.5A) MR9 A 301 (-3.2A)	0.40A	3cs9A-2p4iA: 23.9	3cs9A-2p4iA: 37.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CS9_B_NILB600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	2p4i	ANGIOPOIETIN-1 RECEPTOR (Homo sapiens)	7 / 12	ALA A 853 VAL A 875 GLY A 908 HIS A 962 ALA A 981 ASP A 982 PHE A 983	MR9 A 301 (-3.5A) MR9 A 301 ( 4.8A) MR9 A 301 ( 3.8A) MR9 A 301 (-4.5A) MR9 A 301 (-3.2A) MR9 A 301 (-4.2A) MR9 A 301 (-4.4A)	0.45A	3cs9B-2p4iA: 24.3	3cs9B-2p4iA: 37.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CS9_C_NILC600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	2p4i	ANGIOPOIETIN-1 RECEPTOR (Homo sapiens)	5 / 12	ALA A 853 PHE A 960 HIS A 962 ALA A 981 ASP A 982	MR9 A 301 (-3.5A) MR9 A 301 ( 4.7A) MR9 A 301 (-4.5A) MR9 A 301 (-3.2A) MR9 A 301 (-4.2A)	0.51A	3cs9C-2p4iA: 24.0	3cs9C-2p4iA: 37.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CS9_C_NILC600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	2p4i	ANGIOPOIETIN-1 RECEPTOR (Homo sapiens)	5 / 12	ALA A 853 VAL A 875 HIS A 962 ALA A 981 ASP A 982	MR9 A 301 (-3.5A) MR9 A 301 ( 4.8A) MR9 A 301 (-4.5A) MR9 A 301 (-3.2A) MR9 A 301 (-4.2A)	0.40A	3cs9C-2p4iA: 24.0	3cs9C-2p4iA: 37.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CS9_D_NILD600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	2p4i	ANGIOPOIETIN-1 RECEPTOR (Homo sapiens)	5 / 12	ALA A 853 VAL A 875 GLY A 908 HIS A 962 ALA A 981	MR9 A 301 (-3.5A) MR9 A 301 ( 4.8A) MR9 A 301 ( 3.8A) MR9 A 301 (-4.5A) MR9 A 301 (-3.2A)	0.34A	3cs9D-2p4iA: 23.6	3cs9D-2p4iA: 37.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CS9_D_NILD600_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	2p4i	ANGIOPOIETIN-1 RECEPTOR (Homo sapiens)	4 / 6	VAL A 838 LYS A 855 LEU A 971 ASP A 982	MR9 A 301 (-4.6A) MR9 A 301 ( 4.6A) MR9 A 301 (-4.5A) MR9 A 301 (-4.2A)	0.61A	3cs9D-2p4iA: 23.6	3cs9D-2p4iA: 37.30
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3GCS_A_BAXA401_1 (MITOGEN-ACTIVATED PROTEIN KINASE 14)	2p4i	ANGIOPOIETIN-1 RECEPTOR (Homo sapiens)	7 / 12	VAL A 838 ALA A 853 LEU A 879 LEU A 876 ILE A 886 HIS A 962 ASP A 982	MR9 A 301 (-4.6A) MR9 A 301 (-3.5A) MR9 A 301 (-4.1A) MR9 A 301 ( 4.5A) MR9 A 301 (-4.0A) MR9 A 301 (-4.5A) MR9 A 301 (-4.2A)	1.36A	3gcsA-2p4iA: 17.3	3gcsA-2p4iA: 26.67
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3GP0_A_NILA1_1 (MITOGEN-ACTIVATED PROTEIN KINASE 11)	2p4i	ANGIOPOIETIN-1 RECEPTOR (Homo sapiens)	6 / 12	VAL A 838 ALA A 853 LEU A 876 ILE A 886 HIS A 962 ASP A 982	MR9 A 301 (-4.6A) MR9 A 301 (-3.5A) MR9 A 301 ( 4.5A) MR9 A 301 (-4.0A) MR9 A 301 (-4.5A) MR9 A 301 (-4.2A)	0.82A	3gp0A-2p4iA: 6.6	3gp0A-2p4iA: 25.67
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3HEG_A_BAXA1_1 (MITOGEN-ACTIVATED PROTEIN KINASE 14)	2p4i	ANGIOPOIETIN-1 RECEPTOR (Homo sapiens)	6 / 12	VAL A 838 ALA A 853 LEU A 879 LEU A 876 ILE A 886 ASP A 982	MR9 A 301 (-4.6A) MR9 A 301 (-3.5A) MR9 A 301 (-4.1A) MR9 A 301 ( 4.5A) MR9 A 301 (-4.0A) MR9 A 301 (-4.2A)	1.32A	3hegA-2p4iA: 11.6	3hegA-2p4iA: 25.59
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3HEG_A_BAXA1_1 (MITOGEN-ACTIVATED PROTEIN KINASE 14)	2p4i	ANGIOPOIETIN-1 RECEPTOR (Homo sapiens)	5 / 12	VAL A 838 ALA A 853 LYS A 855 LEU A 876 ASP A 982	MR9 A 301 (-4.6A) MR9 A 301 (-3.5A) MR9 A 301 ( 4.6A) MR9 A 301 ( 4.5A) MR9 A 301 (-4.2A)	0.76A	3hegA-2p4iA: 11.6	3hegA-2p4iA: 25.59
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3IK3_A_0LIA1_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	2p4i	ANGIOPOIETIN-1 RECEPTOR (Homo sapiens)	7 / 12	ALA A 853 ILE A 902 HIS A 962 LEU A 971 ALA A 981 ASP A 982 PHE A 983	MR9 A 301 (-3.5A) MR9 A 301 (-4.1A) MR9 A 301 (-4.5A) MR9 A 301 (-4.5A) MR9 A 301 (-3.2A) MR9 A 301 (-4.2A) MR9 A 301 (-4.4A)	0.45A	3ik3A-2p4iA: 23.5	3ik3A-2p4iA: 38.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3IK3_B_0LIB2_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	2p4i	ANGIOPOIETIN-1 RECEPTOR (Homo sapiens)	7 / 12	ALA A 853 ILE A 902 HIS A 962 LEU A 971 ALA A 981 ASP A 982 PHE A 983	MR9 A 301 (-3.5A) MR9 A 301 (-4.1A) MR9 A 301 (-4.5A) MR9 A 301 (-4.5A) MR9 A 301 (-3.2A) MR9 A 301 (-4.2A) MR9 A 301 (-4.4A)	0.54A	3ik3B-2p4iA: 23.3	3ik3B-2p4iA: 38.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3K5V_A_STIA2_1 (TYROSINE-PROTEIN KINASE ABL1)	2p4i	ANGIOPOIETIN-1 RECEPTOR (Homo sapiens)	6 / 12	VAL A 838 ALA A 853 GLY A 908 LEU A 971 ALA A 981 ASP A 982	MR9 A 301 (-4.6A) MR9 A 301 (-3.5A) MR9 A 301 ( 3.8A) MR9 A 301 (-4.5A) MR9 A 301 (-3.2A) MR9 A 301 (-4.2A)	0.34A	3k5vA-2p4iA: 15.2	3k5vA-2p4iA: 37.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3K5V_B_STIB2_1 (TYROSINE-PROTEIN KINASE ABL1)	2p4i	ANGIOPOIETIN-1 RECEPTOR (Homo sapiens)	6 / 12	VAL A 838 ALA A 853 GLY A 908 LEU A 971 ALA A 981 ASP A 982	MR9 A 301 (-4.6A) MR9 A 301 (-3.5A) MR9 A 301 ( 3.8A) MR9 A 301 (-4.5A) MR9 A 301 (-3.2A) MR9 A 301 (-4.2A)	0.35A	3k5vB-2p4iA: 17.9	3k5vB-2p4iA: 37.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3MS9_B_STIB1_1 (TYROSINE-PROTEIN KINASE ABL1)	2p4i	ANGIOPOIETIN-1 RECEPTOR (Homo sapiens)	6 / 12	VAL A 838 ALA A 853 GLY A 908 LEU A 971 ALA A 981 ASP A 982	MR9 A 301 (-4.6A) MR9 A 301 (-3.5A) MR9 A 301 ( 3.8A) MR9 A 301 (-4.5A) MR9 A 301 (-3.2A) MR9 A 301 (-4.2A)	0.35A	3ms9B-2p4iA: 23.6	3ms9B-2p4iA: 37.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3MSS_B_STIB1_1 (TYROSINE-PROTEIN KINASE ABL1)	2p4i	ANGIOPOIETIN-1 RECEPTOR (Homo sapiens)	6 / 12	VAL A 838 ALA A 853 GLY A 908 LEU A 971 ALA A 981 ASP A 982	MR9 A 301 (-4.6A) MR9 A 301 (-3.5A) MR9 A 301 ( 3.8A) MR9 A 301 (-4.5A) MR9 A 301 (-3.2A) MR9 A 301 (-4.2A)	0.36A	3mssB-2p4iA: 13.1	3mssB-2p4iA: 37.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OEZ_A_STIA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	2p4i	ANGIOPOIETIN-1 RECEPTOR (Homo sapiens)	7 / 12	VAL A 838 ALA A 853 TYR A 904 GLY A 908 LEU A 971 ALA A 981 ASP A 982	MR9 A 301 (-4.6A) MR9 A 301 (-3.5A) MR9 A 301 (-3.8A) MR9 A 301 ( 3.8A) MR9 A 301 (-4.5A) MR9 A 301 (-3.2A) MR9 A 301 (-4.2A)	0.53A	3oezA-2p4iA: 23.8	3oezA-2p4iA: 33.64
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OEZ_B_STIB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	2p4i	ANGIOPOIETIN-1 RECEPTOR (Homo sapiens)	7 / 12	VAL A 838 ALA A 853 VAL A 875 TYR A 904 LEU A 971 ALA A 981 ASP A 982	MR9 A 301 (-4.6A) MR9 A 301 (-3.5A) MR9 A 301 ( 4.8A) MR9 A 301 (-3.8A) MR9 A 301 (-4.5A) MR9 A 301 (-3.2A) MR9 A 301 (-4.2A)	0.83A	3oezB-2p4iA: 24.0	3oezB-2p4iA: 33.64
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OXZ_A_0LIA1_1 (TYROSINE-PROTEIN KINASE ABL1)	2p4i	ANGIOPOIETIN-1 RECEPTOR (Homo sapiens)	6 / 12	ALA A 853 GLY A 908 HIS A 962 ALA A 981 ASP A 982 PHE A 983	MR9 A 301 (-3.5A) MR9 A 301 ( 3.8A) MR9 A 301 (-4.5A) MR9 A 301 (-3.2A) MR9 A 301 (-4.2A) MR9 A 301 (-4.4A)	0.45A	3oxzA-2p4iA: 24.0	3oxzA-2p4iA: 36.56
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3PYY_A_STIA3_1 (V-ABL ABELSON MURINE LEUKEMIA VIRAL ONCOGENE HOMOLOG 1 ISOFORM B VARIANT)	2p4i	ANGIOPOIETIN-1 RECEPTOR (Homo sapiens)	6 / 12	VAL A 838 ALA A 853 GLY A 908 LEU A 971 ALA A 981 ASP A 982	MR9 A 301 (-4.6A) MR9 A 301 (-3.5A) MR9 A 301 ( 3.8A) MR9 A 301 (-4.5A) MR9 A 301 (-3.2A) MR9 A 301 (-4.2A)	0.30A	3pyyA-2p4iA: 24.0	3pyyA-2p4iA: 36.36
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3RGF_A_BAXA465_1 (CYCLIN-DEPENDENT KINASE 8)	2p4i	ANGIOPOIETIN-1 RECEPTOR (Homo sapiens)	9 / 12	VAL A 838 ALA A 853 LEU A 876 ILE A 886 TYR A 904 ALA A 905 LEU A 955 HIS A 962 ALA A 981	MR9 A 301 (-4.6A) MR9 A 301 (-3.5A) MR9 A 301 ( 4.5A) MR9 A 301 (-4.0A) MR9 A 301 (-3.8A) MR9 A 301 (-3.6A) MR9 A 301 (-4.4A) MR9 A 301 (-4.5A) MR9 A 301 (-3.2A)	0.90A	3rgfA-2p4iA: 18.9	3rgfA-2p4iA: 25.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3W1W_A_CHDA1502_0 (FERROCHELATASE, MITOCHONDRIAL)	2p4i	ANGIOPOIETIN-1 RECEPTOR (Homo sapiens)	5 / 12	LEU A 910 LEU A 914 ILE A 980 SER A1033 PRO A1038	None None MR9 A 301 (-4.6A) None None	1.23A	3w1wA-2p4iA: undetectable	3w1wA-2p4iA: 21.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3ZOS_A_0LIA1000_1 (EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1)	2p4i	ANGIOPOIETIN-1 RECEPTOR (Homo sapiens)	7 / 12	ALA A 853 LEU A 955 HIS A 962 LEU A 971 ALA A 981 ASP A 982 PHE A 983	MR9 A 301 (-3.5A) MR9 A 301 (-4.4A) MR9 A 301 (-4.5A) MR9 A 301 (-4.5A) MR9 A 301 (-3.2A) MR9 A 301 (-4.2A) MR9 A 301 (-4.4A)	0.62A	3zosA-2p4iA: 12.4	3zosA-2p4iA: 33.52
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3ZOS_A_0LIA1000_2 (EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1)	2p4i	ANGIOPOIETIN-1 RECEPTOR (Homo sapiens)	5 / 9	LEU A 879 ILE A 885 ILE A 886 TYR A 904 ILE A 980	MR9 A 301 (-4.1A) MR9 A 301 ( 4.5A) MR9 A 301 (-4.0A) MR9 A 301 (-3.8A) MR9 A 301 (-4.6A)	0.72A	3zosA-2p4iA: 13.6	3zosA-2p4iA: 33.52
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3ZOS_B_0LIB1000_1 (EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1)	2p4i	ANGIOPOIETIN-1 RECEPTOR (Homo sapiens)	8 / 12	ALA A 853 ILE A 886 LEU A 955 HIS A 962 LEU A 971 ALA A 981 ASP A 982 PHE A 983	MR9 A 301 (-3.5A) MR9 A 301 (-4.0A) MR9 A 301 (-4.4A) MR9 A 301 (-4.5A) MR9 A 301 (-4.5A) MR9 A 301 (-3.2A) MR9 A 301 (-4.2A) MR9 A 301 (-4.4A)	0.67A	3zosB-2p4iA: 12.2	3zosB-2p4iA: 33.52
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3ZOS_B_0LIB1000_1 (EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1)	2p4i	ANGIOPOIETIN-1 RECEPTOR (Homo sapiens)	7 / 12	ALA A 853 LEU A 955 HIS A 962 ARG A 963 LEU A 971 ALA A 981 ASP A 982	MR9 A 301 (-3.5A) MR9 A 301 (-4.4A) MR9 A 301 (-4.5A) None MR9 A 301 (-4.5A) MR9 A 301 (-3.2A) MR9 A 301 (-4.2A)	0.78A	3zosB-2p4iA: 12.2	3zosB-2p4iA: 33.52
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4BKJ_A_STIA1000_1 (EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1)	2p4i	ANGIOPOIETIN-1 RECEPTOR (Homo sapiens)	7 / 12	VAL A 838 ALA A 853 ILE A 886 TYR A 904 LEU A 971 ALA A 981 ASP A 982	MR9 A 301 (-4.6A) MR9 A 301 (-3.5A) MR9 A 301 (-4.0A) MR9 A 301 (-3.8A) MR9 A 301 (-4.5A) MR9 A 301 (-3.2A) MR9 A 301 (-4.2A)	0.62A	4bkjA-2p4iA: 21.8	4bkjA-2p4iA: 33.52
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4BKJ_B_STIB1000_1 (EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1)	2p4i	ANGIOPOIETIN-1 RECEPTOR (Homo sapiens)	7 / 12	VAL A 838 ALA A 853 ILE A 886 LEU A 971 ALA A 981 ASP A 982 PHE A 983	MR9 A 301 (-4.6A) MR9 A 301 (-3.5A) MR9 A 301 (-4.0A) MR9 A 301 (-4.5A) MR9 A 301 (-3.2A) MR9 A 301 (-4.2A) MR9 A 301 (-4.4A)	0.55A	4bkjB-2p4iA: 9.1	4bkjB-2p4iA: 33.52
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4C8B_A_0LIA1000_2 (RECEPTOR-INTERACTING SERINE/THREONINE-PRO TEIN KINASE 2)	2p4i	ANGIOPOIETIN-1 RECEPTOR (Homo sapiens)	4 / 5	VAL A 838 ILE A 885 TYR A 904 ILE A 980	MR9 A 301 (-4.6A) MR9 A 301 ( 4.5A) MR9 A 301 (-3.8A) MR9 A 301 (-4.6A)	0.80A	4c8bA-2p4iA: 9.8	4c8bA-2p4iA: 25.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4C8B_B_0LIB1000_1 (RECEPTOR-INTERACTING SERINE/THREONINE-PRO TEIN KINASE 2)	2p4i	ANGIOPOIETIN-1 RECEPTOR (Homo sapiens)	7 / 12	ALA A 853 ILE A 885 HIS A 962 LEU A 971 ALA A 981 ASP A 982 PHE A 983	MR9 A 301 (-3.5A) MR9 A 301 ( 4.5A) MR9 A 301 (-4.5A) MR9 A 301 (-4.5A) MR9 A 301 (-3.2A) MR9 A 301 (-4.2A) MR9 A 301 (-4.4A)	0.77A	4c8bB-2p4iA: 11.4	4c8bB-2p4iA: 25.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4CSV_A_STIA1265_1 (SRC-ABL TYROSINE KINASE ANCESTOR)	2p4i	ANGIOPOIETIN-1 RECEPTOR (Homo sapiens)	7 / 12	VAL A 838 ALA A 853 TYR A 904 LEU A 971 ALA A 981 ASP A 982 PHE A 983	MR9 A 301 (-4.6A) MR9 A 301 (-3.5A) MR9 A 301 (-3.8A) MR9 A 301 (-4.5A) MR9 A 301 (-3.2A) MR9 A 301 (-4.2A) MR9 A 301 (-4.4A)	0.45A	4csvA-2p4iA: 24.1	4csvA-2p4iA: 38.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4QRC_A_0LIA802_1 (FIBROBLAST GROWTH FACTOR RECEPTOR 4)	2p4i	ANGIOPOIETIN-1 RECEPTOR (Homo sapiens)	5 / 12	ALA A 853 ARG A 963 ALA A 981 ASP A 982 PHE A 983	MR9 A 301 (-3.5A) None MR9 A 301 (-3.2A) MR9 A 301 (-4.2A) MR9 A 301 (-4.4A)	1.11A	4qrcA-2p4iA: 27.9	4qrcA-2p4iA: 43.15
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4QRC_A_0LIA802_1 (FIBROBLAST GROWTH FACTOR RECEPTOR 4)	2p4i	ANGIOPOIETIN-1 RECEPTOR (Homo sapiens)	5 / 12	ALA A 853 LEU A 955 ARG A 963 ALA A 981 PHE A 983	MR9 A 301 (-3.5A) MR9 A 301 (-4.4A) None MR9 A 301 (-3.2A) MR9 A 301 (-4.4A)	0.68A	4qrcA-2p4iA: 27.9	4qrcA-2p4iA: 43.15
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4QRC_A_0LIA802_2 (FIBROBLAST GROWTH FACTOR RECEPTOR 4)	2p4i	ANGIOPOIETIN-1 RECEPTOR (Homo sapiens)	5 / 8	VAL A 838 LYS A 855 ALA A 905 HIS A 962 LEU A 971	MR9 A 301 (-4.6A) MR9 A 301 ( 4.6A) MR9 A 301 (-3.6A) MR9 A 301 (-4.5A) MR9 A 301 (-4.5A)	0.82A	4qrcA-2p4iA: 27.9	4qrcA-2p4iA: 43.15
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4QRC_A_0LIA802_2 (FIBROBLAST GROWTH FACTOR RECEPTOR 4)	2p4i	ANGIOPOIETIN-1 RECEPTOR (Homo sapiens)	5 / 8	VAL A 838 LYS A 855 ILE A 886 HIS A 962 LEU A 971	MR9 A 301 (-4.6A) MR9 A 301 ( 4.6A) MR9 A 301 (-4.0A) MR9 A 301 (-4.5A) MR9 A 301 (-4.5A)	1.11A	4qrcA-2p4iA: 27.9	4qrcA-2p4iA: 43.15
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4TYJ_A_0LIA801_1 (FIBROBLAST GROWTH FACTOR RECEPTOR 4)	2p4i	ANGIOPOIETIN-1 RECEPTOR (Homo sapiens)	7 / 12	ALA A 853 ALA A 905 HIS A 962 LEU A 971 ALA A 981 ASP A 982 PHE A 983	MR9 A 301 (-3.5A) MR9 A 301 (-3.6A) MR9 A 301 (-4.5A) MR9 A 301 (-4.5A) MR9 A 301 (-3.2A) MR9 A 301 (-4.2A) MR9 A 301 (-4.4A)	0.47A	4tyjA-2p4iA: 17.4	4tyjA-2p4iA: 43.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U0I_A_0LIA1001_2 (MAST/STEM CELL GROWTH FACTOR RECEPTOR KIT,MAST/STEM CELL GROWTH FACTOR RECEPTOR KIT)	2p4i	ANGIOPOIETIN-1 RECEPTOR (Homo sapiens)	7 / 12	ALA A 853 LEU A 876 GLY A 908 HIS A 962 LEU A 971 ASP A 982 PHE A 983	MR9 A 301 (-3.5A) MR9 A 301 ( 4.5A) MR9 A 301 ( 3.8A) MR9 A 301 (-4.5A) MR9 A 301 (-4.5A) MR9 A 301 (-4.2A) MR9 A 301 (-4.4A)	0.80A	4u0iA-2p4iA: 23.8	4u0iA-2p4iA: 39.64
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4UXQ_A_0LIA1752_1 (FIBROBLAST GROWTH FACTOR RECEPTOR 4)	2p4i	ANGIOPOIETIN-1 RECEPTOR (Homo sapiens)	7 / 12	ALA A 853 LEU A 955 HIS A 962 LEU A 971 ALA A 981 ASP A 982 PHE A 983	MR9 A 301 (-3.5A) MR9 A 301 (-4.4A) MR9 A 301 (-4.5A) MR9 A 301 (-4.5A) MR9 A 301 (-3.2A) MR9 A 301 (-4.2A) MR9 A 301 (-4.4A)	0.49A	4uxqA-2p4iA: 26.8	4uxqA-2p4iA: 44.07
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4UXQ_A_0LIA1752_2 (FIBROBLAST GROWTH FACTOR RECEPTOR 4)	2p4i	ANGIOPOIETIN-1 RECEPTOR (Homo sapiens)	4 / 7	LYS A 855 ILE A 886 ALA A 905 ILE A 980	MR9 A 301 ( 4.6A) MR9 A 301 (-4.0A) MR9 A 301 (-3.6A) MR9 A 301 (-4.6A)	0.69A	4uxqA-2p4iA: 26.8	4uxqA-2p4iA: 44.07
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4V01_A_0LIA1776_1 (FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B)	2p4i	ANGIOPOIETIN-1 RECEPTOR (Homo sapiens)	7 / 12	ALA A 853 ALA A 905 LEU A 955 HIS A 962 ALA A 981 ASP A 982 PHE A 983	MR9 A 301 (-3.5A) MR9 A 301 (-3.6A) MR9 A 301 (-4.4A) MR9 A 301 (-4.5A) MR9 A 301 (-3.2A) MR9 A 301 (-4.2A) MR9 A 301 (-4.4A)	0.55A	4v01A-2p4iA: 27.1	4v01A-2p4iA: 42.12
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4V01_A_0LIA1776_1 (FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B)	2p4i	ANGIOPOIETIN-1 RECEPTOR (Homo sapiens)	6 / 12	ALA A 905 LEU A 955 HIS A 962 ALA A 981 ASP A 982 PHE A 983	MR9 A 301 (-3.6A) MR9 A 301 (-4.4A) MR9 A 301 (-4.5A) MR9 A 301 (-3.2A) MR9 A 301 (-4.2A) MR9 A 301 (-4.4A)	1.36A	4v01A-2p4iA: 27.1	4v01A-2p4iA: 42.12
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4V01_A_0LIA1776_2 (FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B)	2p4i	ANGIOPOIETIN-1 RECEPTOR (Homo sapiens)	6 / 9	VAL A 838 LYS A 855 ILE A 886 TYR A 904 LEU A 971 ILE A 980	MR9 A 301 (-4.6A) MR9 A 301 ( 4.6A) MR9 A 301 (-4.0A) MR9 A 301 (-3.8A) MR9 A 301 (-4.5A) MR9 A 301 (-4.6A)	1.03A	4v01A-2p4iA: 27.1	4v01A-2p4iA: 42.12
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4V01_B_0LIB1770_1 (FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B)	2p4i	ANGIOPOIETIN-1 RECEPTOR (Homo sapiens)	7 / 12	ALA A 853 ALA A 905 LEU A 955 HIS A 962 ALA A 981 ASP A 982 PHE A 983	MR9 A 301 (-3.5A) MR9 A 301 (-3.6A) MR9 A 301 (-4.4A) MR9 A 301 (-4.5A) MR9 A 301 (-3.2A) MR9 A 301 (-4.2A) MR9 A 301 (-4.4A)	0.61A	4v01B-2p4iA: 13.0	4v01B-2p4iA: 42.12
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4V01_B_0LIB1770_1 (FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B)	2p4i	ANGIOPOIETIN-1 RECEPTOR (Homo sapiens)	6 / 12	ALA A 905 LEU A 955 HIS A 962 ALA A 981 ASP A 982 PHE A 983	MR9 A 301 (-3.6A) MR9 A 301 (-4.4A) MR9 A 301 (-4.5A) MR9 A 301 (-3.2A) MR9 A 301 (-4.2A) MR9 A 301 (-4.4A)	1.36A	4v01B-2p4iA: 13.0	4v01B-2p4iA: 42.12
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4V04_A_0LIA1772_1 (FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B)	2p4i	ANGIOPOIETIN-1 RECEPTOR (Homo sapiens)	7 / 12	VAL A 838 ALA A 853 ALA A 905 LEU A 955 HIS A 962 ALA A 981 ASP A 982	MR9 A 301 (-4.6A) MR9 A 301 (-3.5A) MR9 A 301 (-3.6A) MR9 A 301 (-4.4A) MR9 A 301 (-4.5A) MR9 A 301 (-3.2A) MR9 A 301 (-4.2A)	0.55A	4v04A-2p4iA: 25.4	4v04A-2p4iA: 42.12
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4V04_A_0LIA1772_2 (FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B)	2p4i	ANGIOPOIETIN-1 RECEPTOR (Homo sapiens)	4 / 8	ILE A 886 LEU A 971 ILE A 980 PHE A 983	MR9 A 301 (-4.0A) MR9 A 301 (-4.5A) MR9 A 301 (-4.6A) MR9 A 301 (-4.4A)	0.70A	4v04A-2p4iA: 25.4	4v04A-2p4iA: 42.12
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4V04_A_0LIA1772_2 (FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B)	2p4i	ANGIOPOIETIN-1 RECEPTOR (Homo sapiens)	4 / 8	TYR A 904 LEU A 971 ILE A 980 PHE A 983	MR9 A 301 (-3.8A) MR9 A 301 (-4.5A) MR9 A 301 (-4.6A) MR9 A 301 (-4.4A)	0.77A	4v04A-2p4iA: 25.4	4v04A-2p4iA: 42.12
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4V04_B_0LIB1771_2 (FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B)	2p4i	ANGIOPOIETIN-1 RECEPTOR (Homo sapiens)	7 / 12	ALA A 853 ALA A 905 LEU A 955 HIS A 962 ALA A 981 ASP A 982 PHE A 983	MR9 A 301 (-3.5A) MR9 A 301 (-3.6A) MR9 A 301 (-4.4A) MR9 A 301 (-4.5A) MR9 A 301 (-3.2A) MR9 A 301 (-4.2A) MR9 A 301 (-4.4A)	0.51A	4v04B-2p4iA: 26.4	4v04B-2p4iA: 42.12
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4V04_B_0LIB1771_2 (FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B)	2p4i	ANGIOPOIETIN-1 RECEPTOR (Homo sapiens)	6 / 12	ALA A 905 LEU A 955 HIS A 962 ALA A 981 ASP A 982 PHE A 983	MR9 A 301 (-3.6A) MR9 A 301 (-4.4A) MR9 A 301 (-4.5A) MR9 A 301 (-3.2A) MR9 A 301 (-4.2A) MR9 A 301 (-4.4A)	1.35A	4v04B-2p4iA: 26.4	4v04B-2p4iA: 42.12
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5AJQ_B_DB8B800_1 (SERINE/THREONINE-PRO TEIN KINASE 10)	2p4i	ANGIOPOIETIN-1 RECEPTOR (Homo sapiens)	5 / 10	ALA A 853 ILE A 902 GLY A 908 LEU A 971 ALA A 981	MR9 A 301 (-3.5A) MR9 A 301 (-4.1A) MR9 A 301 ( 3.8A) MR9 A 301 (-4.5A) MR9 A 301 (-3.2A)	0.67A	5ajqB-2p4iA: 19.1	5ajqB-2p4iA: 28.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5MO4_A_NILA601_2 (TYROSINE-PROTEIN KINASE ABL1)	2p4i	ANGIOPOIETIN-1 RECEPTOR (Homo sapiens)	5 / 12	ALA A 853 ILE A 902 PHE A 960 ALA A 981 ASP A 982	MR9 A 301 (-3.5A) MR9 A 301 (-4.1A) MR9 A 301 ( 4.7A) MR9 A 301 (-3.2A) MR9 A 301 (-4.2A)	0.65A	5mo4A-2p4iA: 22.2	5mo4A-2p4iA: 27.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5MO4_A_NILA601_2 (TYROSINE-PROTEIN KINASE ABL1)	2p4i	ANGIOPOIETIN-1 RECEPTOR (Homo sapiens)	7 / 12	ALA A 853 VAL A 875 ILE A 902 HIS A 962 LEU A 971 ALA A 981 ASP A 982	MR9 A 301 (-3.5A) MR9 A 301 ( 4.8A) MR9 A 301 (-4.1A) MR9 A 301 (-4.5A) MR9 A 301 (-4.5A) MR9 A 301 (-3.2A) MR9 A 301 (-4.2A)	0.50A	5mo4A-2p4iA: 22.2	5mo4A-2p4iA: 27.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5ZV2_A_LEVA801_1 (FIBROBLAST GROWTH FACTOR RECEPTOR 1)	2p4i	ANGIOPOIETIN-1 RECEPTOR (Homo sapiens)	6 / 12	VAL A 838 ALA A 853 TYR A 904 ALA A 905 GLY A 908 ALA A 981	MR9 A 301 (-4.6A) MR9 A 301 (-3.5A) MR9 A 301 (-3.8A) MR9 A 301 (-3.6A) MR9 A 301 ( 3.8A) MR9 A 301 (-3.2A)	0.69A	5zv2A-2p4iA: 25.1	5zv2A-2p4iA: 12.90
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6HD4_A_STIA604_0 (TYROSINE-PROTEIN KINASE ABL1)	2p4i	ANGIOPOIETIN-1 RECEPTOR (Homo sapiens)	6 / 12	VAL A 838 ALA A 853 LYS A 855 LEU A 971 ALA A 981 ASP A 982	MR9 A 301 (-4.6A) MR9 A 301 (-3.5A) MR9 A 301 ( 4.6A) MR9 A 301 (-4.5A) MR9 A 301 (-3.2A) MR9 A 301 (-4.2A)	0.58A	6hd4A-2p4iA: 12.2	6hd4A-2p4iA: 12.80
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6HD4_B_STIB602_0 (TYROSINE-PROTEIN KINASE ABL1)	2p4i	ANGIOPOIETIN-1 RECEPTOR (Homo sapiens)	6 / 12	VAL A 838 ALA A 853 LYS A 855 LEU A 971 ALA A 981 ASP A 982	MR9 A 301 (-4.6A) MR9 A 301 (-3.5A) MR9 A 301 ( 4.6A) MR9 A 301 (-4.5A) MR9 A 301 (-3.2A) MR9 A 301 (-4.2A)	0.56A	6hd4B-2p4iA: 23.9	6hd4B-2p4iA: 12.80

[["DrReposER ID","Desc.","Hit PDB","Hit molecule","Hit organism","Res. no.","Interface","HETATM","RMSD","Z-score","Seq ID"],["1EE2_B_CHDB1250_0","ALCOHOL DEHYDROGENASE","2p4i","ANGIOPOIETIN-1 RECEPTOR","Homo sapiens",3,"MET A 952;LEU A 955;SER A 956","None;MR9 A 301 (-4.4A);None","0.63A","1ee2A-2p4iA:undetectable",null],["1IEP_A_STIA201_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL","2p4i","ANGIOPOIETIN-1 RECEPTOR","Homo sapiens",6,"VAL A 838;ALA A 853;GLY A 908;LEU A 971;ALA A 981;ASP A 982","MR9 A 301 (-4.6A);MR9 A 301 (-3.5A);MR9 A 301 ( 3.8A);MR9 A 301 (-4.5A);MR9 A 301 (-3.2A);MR9 A 301 (-4.2A)","0.31A","1iepA-2p4iA:10.0","1ee2A-2p4iA:21.73"],["2A3A_A_TEPA1436_1","CHITINASE","2p4i","ANGIOPOIETIN-1 RECEPTOR","Homo sapiens",3,"ASP A 982;PHE A 960;ARG A 987","MR9 A 301 (-4.2A);MR9 A 301 ( 4.7A);None","0.83A","2a3aA-2p4iA:undetectable","1iepA-2p4iA:37.70"],["2HYY_A_STIA600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","2p4i","ANGIOPOIETIN-1 RECEPTOR","Homo sapiens",6,"VAL A 838;ALA A 853;GLY A 908;LEU A 971;ALA A 981;ASP A 982","MR9 A 301 (-4.6A);MR9 A 301 (-3.5A);MR9 A 301 ( 3.8A);MR9 A 301 (-4.5A);MR9 A 301 (-3.2A);MR9 A 301 (-4.2A)","0.35A","2hyyA-2p4iA:23.8","2a3aA-2p4iA:22.47"],["2HYY_B_STIB600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","2p4i","ANGIOPOIETIN-1 RECEPTOR","Homo sapiens",6,"VAL A 838;ALA A 853;GLY A 908;LEU A 971;ALA A 981;ASP A 982","MR9 A 301 (-4.6A);MR9 A 301 (-3.5A);MR9 A 301 ( 3.8A);MR9 A 301 (-4.5A);MR9 A 301 (-3.2A);MR9 A 301 (-4.2A)","0.39A","2hyyB-2p4iA:23.8","2hyyA-2p4iA:36.83"],["2HYY_C_STIC600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","2p4i","ANGIOPOIETIN-1 RECEPTOR","Homo sapiens",6,"VAL A 838;ALA A 853;GLY A 908;LEU A 971;ALA A 981;ASP A 982","MR9 A 301 (-4.6A);MR9 A 301 (-3.5A);MR9 A 301 ( 3.8A);MR9 A 301 (-4.5A);MR9 A 301 (-3.2A);MR9 A 301 (-4.2A)","0.45A","2hyyC-2p4iA:23.9","2hyyB-2p4iA:36.83"],["2KCE_A_D16A566_2","THYMIDYLATE SYNTHASE","2p4i","ANGIOPOIETIN-1 RECEPTOR","Homo sapiens",3,"HIS A 962;ILE A 885;LEU A 876","MR9 A 301 (-4.5A);MR9 A 301 ( 4.5A);MR9 A 301 ( 4.5A)","0.76A","2kceA-2p4iA:undetectable","2hyyC-2p4iA:36.83"],["2OIQ_A_STIA1001_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","2p4i","ANGIOPOIETIN-1 RECEPTOR","Homo sapiens",8,"VAL A 838;ALA A 853;LYS A 855;TYR A 904;GLY A 908;LEU A 971;ALA A 981;ASP A 982","MR9 A 301 (-4.6A);MR9 A 301 (-3.5A);MR9 A 301 ( 4.6A);MR9 A 301 (-3.8A);MR9 A 301 ( 3.8A);MR9 A 301 (-4.5A);MR9 A 301 (-3.2A);MR9 A 301 (-4.2A)","0.59A","2oiqA-2p4iA:24.0","2kceA-2p4iA:23.49"],["2PL0_A_STIA200_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK","2p4i","ANGIOPOIETIN-1 RECEPTOR","Homo sapiens",7,"VAL A 838;ALA A 853;LYS A 855;TYR A 904;LEU A 971;ALA A 981;ASP A 982","MR9 A 301 (-4.6A);MR9 A 301 (-3.5A);MR9 A 301 ( 4.6A);MR9 A 301 (-3.8A);MR9 A 301 (-4.5A);MR9 A 301 (-3.2A);MR9 A 301 (-4.2A)","0.54A","2pl0A-2p4iA:22.7","2oiqA-2p4iA:33.95"],["3AQI_B_CHDB6_0","FERROCHELATASE","2p4i","ANGIOPOIETIN-1 RECEPTOR","Homo sapiens",5,"LEU A 910;LEU A 914;ILE A 980;SER A1033;PRO A1038","None;None;MR9 A 301 (-4.6A);None;None","1.14A","3aqiB-2p4iA:undetectable","2pl0A-2p4iA:33.74"],["3CS9_A_NILA600_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","2p4i","ANGIOPOIETIN-1 RECEPTOR","Homo sapiens",6,"ALA A 853;VAL A 875;GLY A 908;HIS A 962;LEU A 971;ALA A 981","MR9 A 301 (-3.5A);MR9 A 301 ( 4.8A);MR9 A 301 ( 3.8A);MR9 A 301 (-4.5A);MR9 A 301 (-4.5A);MR9 A 301 (-3.2A)","0.40A","3cs9A-2p4iA:23.9","3aqiB-2p4iA:21.88"],["3CS9_B_NILB600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","2p4i","ANGIOPOIETIN-1 RECEPTOR","Homo sapiens",7,"ALA A 853;VAL A 875;GLY A 908;HIS A 962;ALA A 981;ASP A 982;PHE A 983","MR9 A 301 (-3.5A);MR9 A 301 ( 4.8A);MR9 A 301 ( 3.8A);MR9 A 301 (-4.5A);MR9 A 301 (-3.2A);MR9 A 301 (-4.2A);MR9 A 301 (-4.4A)","0.45A","3cs9B-2p4iA:24.3","3cs9A-2p4iA:37.30"],["3CS9_C_NILC600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","2p4i","ANGIOPOIETIN-1 RECEPTOR","Homo sapiens",5,"ALA A 853;PHE A 960;HIS A 962;ALA A 981;ASP A 982","MR9 A 301 (-3.5A);MR9 A 301 ( 4.7A);MR9 A 301 (-4.5A);MR9 A 301 (-3.2A);MR9 A 301 (-4.2A)","0.51A","3cs9C-2p4iA:24.0","3cs9B-2p4iA:37.30"],["3CS9_C_NILC600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","2p4i","ANGIOPOIETIN-1 RECEPTOR","Homo sapiens",5,"ALA A 853;VAL A 875;HIS A 962;ALA A 981;ASP A 982","MR9 A 301 (-3.5A);MR9 A 301 ( 4.8A);MR9 A 301 (-4.5A);MR9 A 301 (-3.2A);MR9 A 301 (-4.2A)","0.40A","3cs9C-2p4iA:24.0","3cs9C-2p4iA:37.30"],["3CS9_D_NILD600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","2p4i","ANGIOPOIETIN-1 RECEPTOR","Homo sapiens",5,"ALA A 853;VAL A 875;GLY A 908;HIS A 962;ALA A 981","MR9 A 301 (-3.5A);MR9 A 301 ( 4.8A);MR9 A 301 ( 3.8A);MR9 A 301 (-4.5A);MR9 A 301 (-3.2A)","0.34A","3cs9D-2p4iA:23.6","3cs9C-2p4iA:37.30"],["3CS9_D_NILD600_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","2p4i","ANGIOPOIETIN-1 RECEPTOR","Homo sapiens",4,"VAL A 838;LYS A 855;LEU A 971;ASP A 982","MR9 A 301 (-4.6A);MR9 A 301 ( 4.6A);MR9 A 301 (-4.5A);MR9 A 301 (-4.2A)","0.61A","3cs9D-2p4iA:23.6","3cs9D-2p4iA:37.30"],["3GCS_A_BAXA401_1","MITOGEN-ACTIVATED PROTEIN KINASE 14","2p4i","ANGIOPOIETIN-1 RECEPTOR","Homo sapiens",7,"VAL A 838;ALA A 853;LEU A 879;LEU A 876;ILE A 886;HIS A 962;ASP A 982","MR9 A 301 (-4.6A);MR9 A 301 (-3.5A);MR9 A 301 (-4.1A);MR9 A 301 ( 4.5A);MR9 A 301 (-4.0A);MR9 A 301 (-4.5A);MR9 A 301 (-4.2A)","1.36A","3gcsA-2p4iA:17.3","3cs9D-2p4iA:37.30"],["3GP0_A_NILA1_1","MITOGEN-ACTIVATED PROTEIN KINASE 11","2p4i","ANGIOPOIETIN-1 RECEPTOR","Homo sapiens",6,"VAL A 838;ALA A 853;LEU A 876;ILE A 886;HIS A 962;ASP A 982","MR9 A 301 (-4.6A);MR9 A 301 (-3.5A);MR9 A 301 ( 4.5A);MR9 A 301 (-4.0A);MR9 A 301 (-4.5A);MR9 A 301 (-4.2A)","0.82A","3gp0A-2p4iA:6.6","3gcsA-2p4iA:26.67"],["3HEG_A_BAXA1_1","MITOGEN-ACTIVATED PROTEIN KINASE 14","2p4i","ANGIOPOIETIN-1 RECEPTOR","Homo sapiens",6,"VAL A 838;ALA A 853;LEU A 879;LEU A 876;ILE A 886;ASP A 982","MR9 A 301 (-4.6A);MR9 A 301 (-3.5A);MR9 A 301 (-4.1A);MR9 A 301 ( 4.5A);MR9 A 301 (-4.0A);MR9 A 301 (-4.2A)","1.32A","3hegA-2p4iA:11.6","3gp0A-2p4iA:25.67"],["3HEG_A_BAXA1_1","MITOGEN-ACTIVATED PROTEIN KINASE 14","2p4i","ANGIOPOIETIN-1 RECEPTOR","Homo sapiens",5,"VAL A 838;ALA A 853;LYS A 855;LEU A 876;ASP A 982","MR9 A 301 (-4.6A);MR9 A 301 (-3.5A);MR9 A 301 ( 4.6A);MR9 A 301 ( 4.5A);MR9 A 301 (-4.2A)","0.76A","3hegA-2p4iA:11.6","3hegA-2p4iA:25.59"],["3IK3_A_0LIA1_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","2p4i","ANGIOPOIETIN-1 RECEPTOR","Homo sapiens",7,"ALA A 853;ILE A 902;HIS A 962;LEU A 971;ALA A 981;ASP A 982;PHE A 983","MR9 A 301 (-3.5A);MR9 A 301 (-4.1A);MR9 A 301 (-4.5A);MR9 A 301 (-4.5A);MR9 A 301 (-3.2A);MR9 A 301 (-4.2A);MR9 A 301 (-4.4A)","0.45A","3ik3A-2p4iA:23.5","3hegA-2p4iA:25.59"],["3IK3_B_0LIB2_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","2p4i","ANGIOPOIETIN-1 RECEPTOR","Homo sapiens",7,"ALA A 853;ILE A 902;HIS A 962;LEU A 971;ALA A 981;ASP A 982;PHE A 983","MR9 A 301 (-3.5A);MR9 A 301 (-4.1A);MR9 A 301 (-4.5A);MR9 A 301 (-4.5A);MR9 A 301 (-3.2A);MR9 A 301 (-4.2A);MR9 A 301 (-4.4A)","0.54A","3ik3B-2p4iA:23.3","3ik3A-2p4iA:38.06"],["3K5V_A_STIA2_1","TYROSINE-PROTEIN KINASE ABL1","2p4i","ANGIOPOIETIN-1 RECEPTOR","Homo sapiens",6,"VAL A 838;ALA A 853;GLY A 908;LEU A 971;ALA A 981;ASP A 982","MR9 A 301 (-4.6A);MR9 A 301 (-3.5A);MR9 A 301 ( 3.8A);MR9 A 301 (-4.5A);MR9 A 301 (-3.2A);MR9 A 301 (-4.2A)","0.34A","3k5vA-2p4iA:15.2","3ik3B-2p4iA:38.06"],["3K5V_B_STIB2_1","TYROSINE-PROTEIN KINASE ABL1","2p4i","ANGIOPOIETIN-1 RECEPTOR","Homo sapiens",6,"VAL A 838;ALA A 853;GLY A 908;LEU A 971;ALA A 981;ASP A 982","MR9 A 301 (-4.6A);MR9 A 301 (-3.5A);MR9 A 301 ( 3.8A);MR9 A 301 (-4.5A);MR9 A 301 (-3.2A);MR9 A 301 (-4.2A)","0.35A","3k5vB-2p4iA:17.9","3k5vA-2p4iA:37.70"],["3MS9_B_STIB1_1","TYROSINE-PROTEIN KINASE ABL1","2p4i","ANGIOPOIETIN-1 RECEPTOR","Homo sapiens",6,"VAL A 838;ALA A 853;GLY A 908;LEU A 971;ALA A 981;ASP A 982","MR9 A 301 (-4.6A);MR9 A 301 (-3.5A);MR9 A 301 ( 3.8A);MR9 A 301 (-4.5A);MR9 A 301 (-3.2A);MR9 A 301 (-4.2A)","0.35A","3ms9B-2p4iA:23.6","3k5vB-2p4iA:37.70"],["3MSS_B_STIB1_1","TYROSINE-PROTEIN KINASE ABL1","2p4i","ANGIOPOIETIN-1 RECEPTOR","Homo sapiens",6,"VAL A 838;ALA A 853;GLY A 908;LEU A 971;ALA A 981;ASP A 982","MR9 A 301 (-4.6A);MR9 A 301 (-3.5A);MR9 A 301 ( 3.8A);MR9 A 301 (-4.5A);MR9 A 301 (-3.2A);MR9 A 301 (-4.2A)","0.36A","3mssB-2p4iA:13.1","3ms9B-2p4iA:37.70"],["3OEZ_A_STIA601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","2p4i","ANGIOPOIETIN-1 RECEPTOR","Homo sapiens",7,"VAL A 838;ALA A 853;TYR A 904;GLY A 908;LEU A 971;ALA A 981;ASP A 982","MR9 A 301 (-4.6A);MR9 A 301 (-3.5A);MR9 A 301 (-3.8A);MR9 A 301 ( 3.8A);MR9 A 301 (-4.5A);MR9 A 301 (-3.2A);MR9 A 301 (-4.2A)","0.53A","3oezA-2p4iA:23.8","3mssB-2p4iA:37.70"],["3OEZ_B_STIB601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","2p4i","ANGIOPOIETIN-1 RECEPTOR","Homo sapiens",7,"VAL A 838;ALA A 853;VAL A 875;TYR A 904;LEU A 971;ALA A 981;ASP A 982","MR9 A 301 (-4.6A);MR9 A 301 (-3.5A);MR9 A 301 ( 4.8A);MR9 A 301 (-3.8A);MR9 A 301 (-4.5A);MR9 A 301 (-3.2A);MR9 A 301 (-4.2A)","0.83A","3oezB-2p4iA:24.0","3oezA-2p4iA:33.64"],["3OXZ_A_0LIA1_1","TYROSINE-PROTEIN KINASE ABL1","2p4i","ANGIOPOIETIN-1 RECEPTOR","Homo sapiens",6,"ALA A 853;GLY A 908;HIS A 962;ALA A 981;ASP A 982;PHE A 983","MR9 A 301 (-3.5A);MR9 A 301 ( 3.8A);MR9 A 301 (-4.5A);MR9 A 301 (-3.2A);MR9 A 301 (-4.2A);MR9 A 301 (-4.4A)","0.45A","3oxzA-2p4iA:24.0","3oezB-2p4iA:33.64"],["3PYY_A_STIA3_1","V-ABL ABELSON MURINE LEUKEMIA VIRAL ONCOGENE HOMOLOG 1 ISOFORM B VARIANT","2p4i","ANGIOPOIETIN-1 RECEPTOR","Homo sapiens",6,"VAL A 838;ALA A 853;GLY A 908;LEU A 971;ALA A 981;ASP A 982","MR9 A 301 (-4.6A);MR9 A 301 (-3.5A);MR9 A 301 ( 3.8A);MR9 A 301 (-4.5A);MR9 A 301 (-3.2A);MR9 A 301 (-4.2A)","0.30A","3pyyA-2p4iA:24.0","3oxzA-2p4iA:36.56"],["3RGF_A_BAXA465_1","CYCLIN-DEPENDENT KINASE 8","2p4i","ANGIOPOIETIN-1 RECEPTOR","Homo sapiens",9,"VAL A 838;ALA A 853;LEU A 876;ILE A 886;TYR A 904;ALA A 905;LEU A 955;HIS A 962;ALA A 981","MR9 A 301 (-4.6A);MR9 A 301 (-3.5A);MR9 A 301 ( 4.5A);MR9 A 301 (-4.0A);MR9 A 301 (-3.8A);MR9 A 301 (-3.6A);MR9 A 301 (-4.4A);MR9 A 301 (-4.5A);MR9 A 301 (-3.2A)","0.90A","3rgfA-2p4iA:18.9","3pyyA-2p4iA:36.36"],["3W1W_A_CHDA1502_0","FERROCHELATASE, MITOCHONDRIAL","2p4i","ANGIOPOIETIN-1 RECEPTOR","Homo sapiens",5,"LEU A 910;LEU A 914;ILE A 980;SER A1033;PRO A1038","None;None;MR9 A 301 (-4.6A);None;None","1.23A","3w1wA-2p4iA:undetectable","3rgfA-2p4iA:25.24"],["3ZOS_A_0LIA1000_1","EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1","2p4i","ANGIOPOIETIN-1 RECEPTOR","Homo sapiens",7,"ALA A 853;LEU A 955;HIS A 962;LEU A 971;ALA A 981;ASP A 982;PHE A 983","MR9 A 301 (-3.5A);MR9 A 301 (-4.4A);MR9 A 301 (-4.5A);MR9 A 301 (-4.5A);MR9 A 301 (-3.2A);MR9 A 301 (-4.2A);MR9 A 301 (-4.4A)","0.62A","3zosA-2p4iA:12.4","3w1wA-2p4iA:21.71"],["3ZOS_A_0LIA1000_2","EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1","2p4i","ANGIOPOIETIN-1 RECEPTOR","Homo sapiens",5,"LEU A 879;ILE A 885;ILE A 886;TYR A 904;ILE A 980","MR9 A 301 (-4.1A);MR9 A 301 ( 4.5A);MR9 A 301 (-4.0A);MR9 A 301 (-3.8A);MR9 A 301 (-4.6A)","0.72A","3zosA-2p4iA:13.6","3zosA-2p4iA:33.52"],["3ZOS_B_0LIB1000_1","EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1","2p4i","ANGIOPOIETIN-1 RECEPTOR","Homo sapiens",8,"ALA A 853;ILE A 886;LEU A 955;HIS A 962;LEU A 971;ALA A 981;ASP A 982;PHE A 983","MR9 A 301 (-3.5A);MR9 A 301 (-4.0A);MR9 A 301 (-4.4A);MR9 A 301 (-4.5A);MR9 A 301 (-4.5A);MR9 A 301 (-3.2A);MR9 A 301 (-4.2A);MR9 A 301 (-4.4A)","0.67A","3zosB-2p4iA:12.2","3zosA-2p4iA:33.52"],["3ZOS_B_0LIB1000_1","EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1","2p4i","ANGIOPOIETIN-1 RECEPTOR","Homo sapiens",7,"ALA A 853;LEU A 955;HIS A 962;ARG A 963;LEU A 971;ALA A 981;ASP A 982","MR9 A 301 (-3.5A);MR9 A 301 (-4.4A);MR9 A 301 (-4.5A);None;MR9 A 301 (-4.5A);MR9 A 301 (-3.2A);MR9 A 301 (-4.2A)","0.78A","3zosB-2p4iA:12.2","3zosB-2p4iA:33.52"],["4BKJ_A_STIA1000_1","EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1","2p4i","ANGIOPOIETIN-1 RECEPTOR","Homo sapiens",7,"VAL A 838;ALA A 853;ILE A 886;TYR A 904;LEU A 971;ALA A 981;ASP A 982","MR9 A 301 (-4.6A);MR9 A 301 (-3.5A);MR9 A 301 (-4.0A);MR9 A 301 (-3.8A);MR9 A 301 (-4.5A);MR9 A 301 (-3.2A);MR9 A 301 (-4.2A)","0.62A","4bkjA-2p4iA:21.8","3zosB-2p4iA:33.52"],["4BKJ_B_STIB1000_1","EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1","2p4i","ANGIOPOIETIN-1 RECEPTOR","Homo sapiens",7,"VAL A 838;ALA A 853;ILE A 886;LEU A 971;ALA A 981;ASP A 982;PHE A 983","MR9 A 301 (-4.6A);MR9 A 301 (-3.5A);MR9 A 301 (-4.0A);MR9 A 301 (-4.5A);MR9 A 301 (-3.2A);MR9 A 301 (-4.2A);MR9 A 301 (-4.4A)","0.55A","4bkjB-2p4iA:9.1","4bkjA-2p4iA:33.52"],["4C8B_A_0LIA1000_2","RECEPTOR-INTERACTING SERINE\/THREONINE-PROTEIN KINASE 2","2p4i","ANGIOPOIETIN-1 RECEPTOR","Homo sapiens",4,"VAL A 838;ILE A 885;TYR A 904;ILE A 980","MR9 A 301 (-4.6A);MR9 A 301 ( 4.5A);MR9 A 301 (-3.8A);MR9 A 301 (-4.6A)","0.80A","4c8bA-2p4iA:9.8","4bkjB-2p4iA:33.52"],["4C8B_B_0LIB1000_1","RECEPTOR-INTERACTING SERINE\/THREONINE-PROTEIN KINASE 2","2p4i","ANGIOPOIETIN-1 RECEPTOR","Homo sapiens",7,"ALA A 853;ILE A 885;HIS A 962;LEU A 971;ALA A 981;ASP A 982;PHE A 983","MR9 A 301 (-3.5A);MR9 A 301 ( 4.5A);MR9 A 301 (-4.5A);MR9 A 301 (-4.5A);MR9 A 301 (-3.2A);MR9 A 301 (-4.2A);MR9 A 301 (-4.4A)","0.77A","4c8bB-2p4iA:11.4","4c8bA-2p4iA:25.75"],["4CSV_A_STIA1265_1","SRC-ABL TYROSINE KINASE ANCESTOR","2p4i","ANGIOPOIETIN-1 RECEPTOR","Homo sapiens",7,"VAL A 838;ALA A 853;TYR A 904;LEU A 971;ALA A 981;ASP A 982;PHE A 983","MR9 A 301 (-4.6A);MR9 A 301 (-3.5A);MR9 A 301 (-3.8A);MR9 A 301 (-4.5A);MR9 A 301 (-3.2A);MR9 A 301 (-4.2A);MR9 A 301 (-4.4A)","0.45A","4csvA-2p4iA:24.1","4c8bB-2p4iA:25.75"],["4QRC_A_0LIA802_1","FIBROBLAST GROWTH FACTOR RECEPTOR 4","2p4i","ANGIOPOIETIN-1 RECEPTOR","Homo sapiens",5,"ALA A 853;ARG A 963;ALA A 981;ASP A 982;PHE A 983","MR9 A 301 (-3.5A);None;MR9 A 301 (-3.2A);MR9 A 301 (-4.2A);MR9 A 301 (-4.4A)","1.11A","4qrcA-2p4iA:27.9","4csvA-2p4iA:38.39"],["4QRC_A_0LIA802_1","FIBROBLAST GROWTH FACTOR RECEPTOR 4","2p4i","ANGIOPOIETIN-1 RECEPTOR","Homo sapiens",5,"ALA A 853;LEU A 955;ARG A 963;ALA A 981;PHE A 983","MR9 A 301 (-3.5A);MR9 A 301 (-4.4A);None;MR9 A 301 (-3.2A);MR9 A 301 (-4.4A)","0.68A","4qrcA-2p4iA:27.9","4qrcA-2p4iA:43.15"],["4QRC_A_0LIA802_2","FIBROBLAST GROWTH FACTOR RECEPTOR 4","2p4i","ANGIOPOIETIN-1 RECEPTOR","Homo sapiens",5,"VAL A 838;LYS A 855;ALA A 905;HIS A 962;LEU A 971","MR9 A 301 (-4.6A);MR9 A 301 ( 4.6A);MR9 A 301 (-3.6A);MR9 A 301 (-4.5A);MR9 A 301 (-4.5A)","0.82A","4qrcA-2p4iA:27.9","4qrcA-2p4iA:43.15"],["4QRC_A_0LIA802_2","FIBROBLAST GROWTH FACTOR RECEPTOR 4","2p4i","ANGIOPOIETIN-1 RECEPTOR","Homo sapiens",5,"VAL A 838;LYS A 855;ILE A 886;HIS A 962;LEU A 971","MR9 A 301 (-4.6A);MR9 A 301 ( 4.6A);MR9 A 301 (-4.0A);MR9 A 301 (-4.5A);MR9 A 301 (-4.5A)","1.11A","4qrcA-2p4iA:27.9","4qrcA-2p4iA:43.15"],["4TYJ_A_0LIA801_1","FIBROBLAST GROWTH FACTOR RECEPTOR 4","2p4i","ANGIOPOIETIN-1 RECEPTOR","Homo sapiens",7,"ALA A 853;ALA A 905;HIS A 962;LEU A 971;ALA A 981;ASP A 982;PHE A 983","MR9 A 301 (-3.5A);MR9 A 301 (-3.6A);MR9 A 301 (-4.5A);MR9 A 301 (-4.5A);MR9 A 301 (-3.2A);MR9 A 301 (-4.2A);MR9 A 301 (-4.4A)","0.47A","4tyjA-2p4iA:17.4","4qrcA-2p4iA:43.15"],["4U0I_A_0LIA1001_2","MAST\/STEM CELL GROWTH FACTOR RECEPTOR KIT,MAST\/STEM CELL GROWTH FACTOR RECEPTOR KIT","2p4i","ANGIOPOIETIN-1 RECEPTOR","Homo sapiens",7,"ALA A 853;LEU A 876;GLY A 908;HIS A 962;LEU A 971;ASP A 982;PHE A 983","MR9 A 301 (-3.5A);MR9 A 301 ( 4.5A);MR9 A 301 ( 3.8A);MR9 A 301 (-4.5A);MR9 A 301 (-4.5A);MR9 A 301 (-4.2A);MR9 A 301 (-4.4A)","0.80A","4u0iA-2p4iA:23.8","4tyjA-2p4iA:43.81"],["4UXQ_A_0LIA1752_1","FIBROBLAST GROWTH FACTOR RECEPTOR 4","2p4i","ANGIOPOIETIN-1 RECEPTOR","Homo sapiens",7,"ALA A 853;LEU A 955;HIS A 962;LEU A 971;ALA A 981;ASP A 982;PHE A 983","MR9 A 301 (-3.5A);MR9 A 301 (-4.4A);MR9 A 301 (-4.5A);MR9 A 301 (-4.5A);MR9 A 301 (-3.2A);MR9 A 301 (-4.2A);MR9 A 301 (-4.4A)","0.49A","4uxqA-2p4iA:26.8","4u0iA-2p4iA:39.64"],["4UXQ_A_0LIA1752_2","FIBROBLAST GROWTH FACTOR RECEPTOR 4","2p4i","ANGIOPOIETIN-1 RECEPTOR","Homo sapiens",4,"LYS A 855;ILE A 886;ALA A 905;ILE A 980","MR9 A 301 ( 4.6A);MR9 A 301 (-4.0A);MR9 A 301 (-3.6A);MR9 A 301 (-4.6A)","0.69A","4uxqA-2p4iA:26.8","4uxqA-2p4iA:44.07"],["4V01_A_0LIA1776_1","FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B","2p4i","ANGIOPOIETIN-1 RECEPTOR","Homo sapiens",7,"ALA A 853;ALA A 905;LEU A 955;HIS A 962;ALA A 981;ASP A 982;PHE A 983","MR9 A 301 (-3.5A);MR9 A 301 (-3.6A);MR9 A 301 (-4.4A);MR9 A 301 (-4.5A);MR9 A 301 (-3.2A);MR9 A 301 (-4.2A);MR9 A 301 (-4.4A)","0.55A","4v01A-2p4iA:27.1","4uxqA-2p4iA:44.07"],["4V01_A_0LIA1776_1","FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B","2p4i","ANGIOPOIETIN-1 RECEPTOR","Homo sapiens",6,"ALA A 905;LEU A 955;HIS A 962;ALA A 981;ASP A 982;PHE A 983","MR9 A 301 (-3.6A);MR9 A 301 (-4.4A);MR9 A 301 (-4.5A);MR9 A 301 (-3.2A);MR9 A 301 (-4.2A);MR9 A 301 (-4.4A)","1.36A","4v01A-2p4iA:27.1","4v01A-2p4iA:42.12"],["4V01_A_0LIA1776_2","FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B","2p4i","ANGIOPOIETIN-1 RECEPTOR","Homo sapiens",6,"VAL A 838;LYS A 855;ILE A 886;TYR A 904;LEU A 971;ILE A 980","MR9 A 301 (-4.6A);MR9 A 301 ( 4.6A);MR9 A 301 (-4.0A);MR9 A 301 (-3.8A);MR9 A 301 (-4.5A);MR9 A 301 (-4.6A)","1.03A","4v01A-2p4iA:27.1","4v01A-2p4iA:42.12"],["4V01_B_0LIB1770_1","FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B","2p4i","ANGIOPOIETIN-1 RECEPTOR","Homo sapiens",7,"ALA A 853;ALA A 905;LEU A 955;HIS A 962;ALA A 981;ASP A 982;PHE A 983","MR9 A 301 (-3.5A);MR9 A 301 (-3.6A);MR9 A 301 (-4.4A);MR9 A 301 (-4.5A);MR9 A 301 (-3.2A);MR9 A 301 (-4.2A);MR9 A 301 (-4.4A)","0.61A","4v01B-2p4iA:13.0","4v01A-2p4iA:42.12"],["4V01_B_0LIB1770_1","FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B","2p4i","ANGIOPOIETIN-1 RECEPTOR","Homo sapiens",6,"ALA A 905;LEU A 955;HIS A 962;ALA A 981;ASP A 982;PHE A 983","MR9 A 301 (-3.6A);MR9 A 301 (-4.4A);MR9 A 301 (-4.5A);MR9 A 301 (-3.2A);MR9 A 301 (-4.2A);MR9 A 301 (-4.4A)","1.36A","4v01B-2p4iA:13.0","4v01B-2p4iA:42.12"],["4V04_A_0LIA1772_1","FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B","2p4i","ANGIOPOIETIN-1 RECEPTOR","Homo sapiens",7,"VAL A 838;ALA A 853;ALA A 905;LEU A 955;HIS A 962;ALA A 981;ASP A 982","MR9 A 301 (-4.6A);MR9 A 301 (-3.5A);MR9 A 301 (-3.6A);MR9 A 301 (-4.4A);MR9 A 301 (-4.5A);MR9 A 301 (-3.2A);MR9 A 301 (-4.2A)","0.55A","4v04A-2p4iA:25.4","4v01B-2p4iA:42.12"],["4V04_A_0LIA1772_2","FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B","2p4i","ANGIOPOIETIN-1 RECEPTOR","Homo sapiens",4,"ILE A 886;LEU A 971;ILE A 980;PHE A 983","MR9 A 301 (-4.0A);MR9 A 301 (-4.5A);MR9 A 301 (-4.6A);MR9 A 301 (-4.4A)","0.70A","4v04A-2p4iA:25.4","4v04A-2p4iA:42.12"],["4V04_A_0LIA1772_2","FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B","2p4i","ANGIOPOIETIN-1 RECEPTOR","Homo sapiens",4,"TYR A 904;LEU A 971;ILE A 980;PHE A 983","MR9 A 301 (-3.8A);MR9 A 301 (-4.5A);MR9 A 301 (-4.6A);MR9 A 301 (-4.4A)","0.77A","4v04A-2p4iA:25.4","4v04A-2p4iA:42.12"],["4V04_B_0LIB1771_2","FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B","2p4i","ANGIOPOIETIN-1 RECEPTOR","Homo sapiens",7,"ALA A 853;ALA A 905;LEU A 955;HIS A 962;ALA A 981;ASP A 982;PHE A 983","MR9 A 301 (-3.5A);MR9 A 301 (-3.6A);MR9 A 301 (-4.4A);MR9 A 301 (-4.5A);MR9 A 301 (-3.2A);MR9 A 301 (-4.2A);MR9 A 301 (-4.4A)","0.51A","4v04B-2p4iA:26.4","4v04A-2p4iA:42.12"],["4V04_B_0LIB1771_2","FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B","2p4i","ANGIOPOIETIN-1 RECEPTOR","Homo sapiens",6,"ALA A 905;LEU A 955;HIS A 962;ALA A 981;ASP A 982;PHE A 983","MR9 A 301 (-3.6A);MR9 A 301 (-4.4A);MR9 A 301 (-4.5A);MR9 A 301 (-3.2A);MR9 A 301 (-4.2A);MR9 A 301 (-4.4A)","1.35A","4v04B-2p4iA:26.4","4v04B-2p4iA:42.12"],["5AJQ_B_DB8B800_1","SERINE\/THREONINE-PROTEIN KINASE 10","2p4i","ANGIOPOIETIN-1 RECEPTOR","Homo sapiens",5,"ALA A 853;ILE A 902;GLY A 908;LEU A 971;ALA A 981","MR9 A 301 (-3.5A);MR9 A 301 (-4.1A);MR9 A 301 ( 3.8A);MR9 A 301 (-4.5A);MR9 A 301 (-3.2A)","0.67A","5ajqB-2p4iA:19.1","4v04B-2p4iA:42.12"],["5MO4_A_NILA601_2","TYROSINE-PROTEIN KINASE ABL1","2p4i","ANGIOPOIETIN-1 RECEPTOR","Homo sapiens",5,"ALA A 853;ILE A 902;PHE A 960;ALA A 981;ASP A 982","MR9 A 301 (-3.5A);MR9 A 301 (-4.1A);MR9 A 301 ( 4.7A);MR9 A 301 (-3.2A);MR9 A 301 (-4.2A)","0.65A","5mo4A-2p4iA:22.2","5ajqB-2p4iA:28.13"],["5MO4_A_NILA601_2","TYROSINE-PROTEIN KINASE ABL1","2p4i","ANGIOPOIETIN-1 RECEPTOR","Homo sapiens",7,"ALA A 853;VAL A 875;ILE A 902;HIS A 962;LEU A 971;ALA A 981;ASP A 982","MR9 A 301 (-3.5A);MR9 A 301 ( 4.8A);MR9 A 301 (-4.1A);MR9 A 301 (-4.5A);MR9 A 301 (-4.5A);MR9 A 301 (-3.2A);MR9 A 301 (-4.2A)","0.50A","5mo4A-2p4iA:22.2","5mo4A-2p4iA:27.69"],["5ZV2_A_LEVA801_1","FIBROBLAST GROWTH FACTOR RECEPTOR 1","2p4i","ANGIOPOIETIN-1 RECEPTOR","Homo sapiens",6,"VAL A 838;ALA A 853;TYR A 904;ALA A 905;GLY A 908;ALA A 981","MR9 A 301 (-4.6A);MR9 A 301 (-3.5A);MR9 A 301 (-3.8A);MR9 A 301 (-3.6A);MR9 A 301 ( 3.8A);MR9 A 301 (-3.2A)","0.69A","5zv2A-2p4iA:25.1","5mo4A-2p4iA:27.69"],["6HD4_A_STIA604_0","TYROSINE-PROTEIN KINASE ABL1","2p4i","ANGIOPOIETIN-1 RECEPTOR","Homo sapiens",6,"VAL A 838;ALA A 853;LYS A 855;LEU A 971;ALA A 981;ASP A 982","MR9 A 301 (-4.6A);MR9 A 301 (-3.5A);MR9 A 301 ( 4.6A);MR9 A 301 (-4.5A);MR9 A 301 (-3.2A);MR9 A 301 (-4.2A)","0.58A","6hd4A-2p4iA:12.2","5zv2A-2p4iA:12.90"],["6HD4_B_STIB602_0","TYROSINE-PROTEIN KINASE ABL1","2p4i","ANGIOPOIETIN-1 RECEPTOR","Homo sapiens",6,"VAL A 838;ALA A 853;LYS A 855;LEU A 971;ALA A 981;ASP A 982","MR9 A 301 (-4.6A);MR9 A 301 (-3.5A);MR9 A 301 ( 4.6A);MR9 A 301 (-4.5A);MR9 A 301 (-3.2A);MR9 A 301 (-4.2A)","0.56A","6hd4B-2p4iA:23.9","6hd4A-2p4iA:12.80"]]